A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

Trial information

Medical condition

MDS

Trial phase

Phase 3

Sponsor

Takeda

Start date

29/09/2026

Main objective

To compare the efficacy and safety of elritercept versus epoetin alfa for transfusion-dependent anemia in ESA-naïve lower-risk MDS, with RBC transfusion independence as the primary endpoint.

Locations and Contact points